HC Wainwright Issues Pessimistic Outlook for ABEO Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities researchers at HC Wainwright decreased their Q1 2026 EPS estimates for Abeona Therapeutics in a report released on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.32) per share for the quarter, down from their prior estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.14) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at $0.01 EPS and FY2027 earnings at ($0.47) EPS.

Several other research firms also recently weighed in on ABEO. Stifel Nicolaus set a $17.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, March 17th. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $4.45 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.93 and a quick ratio of 6.74. The stock has a market cap of $253.87 million, a price-to-earnings ratio of 4.32 and a beta of 1.13. The firm has a 50-day moving average of $5.07 and a two-hundred day moving average of $5.18. Abeona Therapeutics has a 1 year low of $3.93 and a 1 year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.01. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.65 million.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its holdings in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after acquiring an additional 66,422 shares during the period. Geode Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after purchasing an additional 623,243 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Abeona Therapeutics during the second quarter valued at about $63,000. Creative Planning boosted its position in Abeona Therapeutics by 43.0% during the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 4,305 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in Abeona Therapeutics in the second quarter valued at about $120,000. Institutional investors own 80.56% of the company’s stock.

Insider Buying and Selling at Abeona Therapeutics

In other news, Director Leila Alland sold 18,065 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $91,950.85. Following the transaction, the director directly owned 173,614 shares in the company, valued at approximately $883,695.26. This trade represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine Berni Silverstein sold 20,070 shares of Abeona Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $102,156.30. Following the transaction, the director directly owned 137,722 shares in the company, valued at approximately $701,004.98. The trade was a 12.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 209,605 shares of company stock worth $1,101,300. 5.40% of the stock is currently owned by company insiders.

Abeona Therapeutics News Summary

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $20.00 price target — a large upside vs. the current market price, which supports a bullish view if Abeona hits upcoming clinical or financial milestones. HC Wainwright Reiterates Buy
• Positive Sentiment: Analyst model shows potential recovery by 2027 (FY2027 EPS forecast of ($0.47) and a small positive EPS in Q4 2027), signaling HC Wainwright expects the company to narrow losses and approach profitability toward late 2027. MarketBeat ABEO
• Neutral Sentiment: HC Wainwright published a full set of quarter-by-quarter estimates through FY2027, providing a new baseline for investors to compare company results against. These estimates will be used as the reference for future beats/misses. MarketBeat ABEO
• Negative Sentiment: HC Wainwright trimmed several near‑term forecasts — including lowering FY2026 EPS to ($1.14) (from prior ~$0.97) and cutting Q1–Q3 2026 and Q4 2026 estimates — indicating higher expected losses in the near term and raising downside risk if revenue/cost trends don’t improve. MarketBeat ABEO
• Negative Sentiment: Multiple downward revisions to quarterly EPS for 2026 increase the odds of near‑term volatility around upcoming quarterly reports and any clinical updates. Expect the stock to be sensitive to any deviation from these lowered targets. MarketBeat ABEO

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.